Unparalleled in its scope and depth, this book brings together proteomic approaches in diagnosis and treatment from all clinical fields, including clinical toxicology. The result is a new discipline in molecular medicine that will revolutionize the treatment and prevention of cancer, stroke and other severe diseases.
Following an overview of clinical proteomics, the authors look at the technologies available, before moving on to cancer, cardiopulmonary disease, diabetes and stroke. A whole section is devoted to toxicity and the work is rounded off with a discussion of the future of clinical proteomics.

Jennifer Van Eyk is the Director of the Johns Hopkins Bayview Proteomics Center and Professor of Medicine, Biological Chemistry and Biomedical Engineering at Johns Hopkins University in Baltimore, Maryland. She has developed novel methods to investigate heart disease including preconditioning, ischemic injury and heart failure with emphasis on both understanding the underlying pathological mechanism and for the development of diagnostic biomarkers. Dr. Van Eyk sits on numerous editorial boards including Proteomics, Proteomics: clinical application, Journal of Physiology and Circulation Research.



Michael J. Dunn was recently appointed as Professor of Biomedical Proteomics at University College, Dublin (Ireland), where he is doing proteomics research in the areas of cardiovascular disease, transplantation and neurological disease. Prior to his move to Dublin, he was Professor of Proteomics at the Institute of Psychiatry, King's College London.
Dr. Dunn is the current President of the British Society for Proteome Research and the Editor-in-Chief of the journal Proteomics. He is also a founder Council Member of the Human Proteome Organisation (HUPO) and a member of the Executive Committee of the HUPO Brain Proteome Project (BPP).